These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38748324)

  • 21. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
    Kaddu-Mulindwa D; Altmann B; Held G; Angel S; Stilgenbauer S; Thurner L; Bewarder M; Schwier M; Pfreundschuh M; Löffler M; Menhart K; Grosse J; Ziepert M; Herrmann K; Dührsen U; Hüttmann A; Barbato F; Poeschel V; Hellwig D
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3550-3559. PubMed ID: 33928400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using
    Hao B; Zhao L; Luo NN; Ruan D; Pang YZ; Guo W; Fu H; Guo XY; Luo ZM; Wu J; Chen HJ; Wu H; Sun L
    BMC Cancer; 2018 Nov; 18(1):1192. PubMed ID: 30497426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
    Pakos EE; Fotopoulos AD; Ioannidis JP
    J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing bone marrow involvement in diffuse large B-cell lymphoma with 18F-FDG PET/CT: A preliminary experience at Hospital Pulau Pinang.
    Siti Maisarah MN; Mahayuddin AM; Fadzilah H
    Med J Malaysia; 2021 Sep; 76(5):665-671. PubMed ID: 34508372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma.
    Badr S; Kotb M; Elahmadawy MA; Moustafa H
    Clin Nucl Med; 2018 Dec; 43(12):e428-e438. PubMed ID: 30358625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of bone marrow involvement in newly diagnosed post-transplant lymphoproliferative disorder: (18)F-fluorodeoxyglucose positron emission tomography/computed tomography versus bone marrow biopsy.
    Gheysens O; Thielemans S; Morscio J; Boeckx N; Goffin KE; Deroose CM; Sagaert X; Wlodarska I; Verhoef G; Dierickx D; Tousseyn T
    Leuk Lymphoma; 2016 Oct; 57(10):2382-8. PubMed ID: 26854937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Italian Multicenter Study on Accuracy of
    Cistaro A; Cassalia L; Ferrara C; Quartuccio N; Evangelista L; Bianchi M; Fagioli F; Bisi G; Baldari S; Zanella A; Pillon M; Zucchetta P; Burei M; Sala A; Guerra L; Guglielmo P; Burnelli R; Panareo S; Scalorbi F; Rambaldi I; Piccardo A; Garaventa A; Familiari D; Fornito MC; Lopci E; Mascarin M; Altini C; Ferrari C; Perillo T; Santoro N; Borsatti E; Rubini G
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e267-e273. PubMed ID: 29739722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
    Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
    J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic performance of integrated whole-body
    Chen X; Yuan T; Wei M; Yu B; Zhou N; Zhu H; Yang Z; Wang X
    Front Oncol; 2023; 13():1136687. PubMed ID: 36994205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of bone marrow biopsy and fluorodeoxyglucose-positron emission tomography for the assessment of bone marrow infiltration in children with Hodgkin's lymphoma.
    Arslantaş E; Ayçiçek A; Akıcı F; Özkara S; Yılmaz B; Özdemir N; Bayram C
    Nuklearmedizin; 2023 Feb; 62(1):20-26. PubMed ID: 36746148
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Yang C; Wu W; Zhou H; Zhao S; Tian R; Xiang M; Zou L
    Front Oncol; 2022; 12():894804. PubMed ID: 35965550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
    Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
    Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of 2-(fluorine-18) Fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography in Initial Staging and Bone Marrow Involvement Prediction in Patients with Newly Diagnosed Lymphoma in Correlation with Bone Marrow Study.
    Krishna S; Ravina M; Nanda S; Lukose TT; Moideen A; Bansal H; Dasgupta S; Kote R
    Indian J Nucl Med; 2024; 39(1):10-17. PubMed ID: 38817719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?
    Çetin G; Çıkrıkçıoğlu MA; Özkan T; Karatoprak C; Ar MC; Eşkazan AE; Ayer M; Cerit A; Gözübenli K; Uysal BB; Erdem S; Ergül N; Tatar G; Çermik TF
    Turk J Haematol; 2015 Sep; 32(3):213-9. PubMed ID: 25912844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole body MRI with qualitative and quantitative analysis of DWI for assessment of bone marrow involvement in lymphoma.
    Balbo-Mussetto A; Saviolo C; Fornari A; Gottardi D; Petracchini M; Macera A; Lario CV; Gallo T; Tarella C; Cirillo S
    Radiol Med; 2017 Aug; 122(8):623-632. PubMed ID: 28421406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
    Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
    Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.